SCHEMBL5540430

SCHEMBL5540430

[CH2]CCCCCC(=O)N1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
NPSR1 Q6W5P4 2/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
SMN1; SMN2 Q16637 8/20 0.53
NPC1 O15118 6/20 0.53
RAB9A P51151 6/20 0.53
MAPT P10636 3/20 0.52
GAA P10253 1/20 0.52
CYP2C19 P33261 1/20 0.51
LMNA P02545 1/20 0.49
ALDH1A1 P00352 2/20 0.46
TSHR P16473 1/20 0.46
DPP4 P27487 1/20 0.44
F13A1 P00488 1/20 0.44
TGM2 P21980 1/20 0.44
TGM1 P22735 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
ADRA2B P18089 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537274 0.95 L3MBTL1 (0.58) L3MBTL1NPSR1MEN1KMT2ASMN1; SMN2
SCHEMBL5536216 0.89 L3MBTL1 (0.60) L3MBTL1NPSR1MEN1KMT2ASMN1; SMN2
SCHEMBL13965300 0.85 L3MBTL1 (0.53) L3MBTL1NPSR1MEN1KMT2ASMN1; SMN2
SCHEMBL27610472 0.85 NPSR1 (0.54) L3MBTL1NPSR1MEN1KMT2ASMN1; SMN2
SCHEMBL5538480 0.84 ENPP2 (0.45) L3MBTL1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL31596932 0.84 SIGMAR1 (0.61) L3MBTL1NPSR1MEN1KMT2ASMN1; SMN2
SCHEMBL6388570 0.84 MEN1 (0.62) L3MBTL1NPSR1MEN1KMT2ASMN1; SMN2
Hydrochloric Acid SCHEMBL30111727 0.83 SIGMAR1 (0.60) L3MBTL1NPSR1MEN1KMT2ASMN1; SMN2
SCHEMBL5542172 0.83 NPSR1 (0.56) L3MBTL1NPSR1MEN1KMT2ASMN1; SMN2
SCHEMBL5545185 0.83 ENPP2 (0.46) L3MBTL1NPSR1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 L3MBTL1 1931/4885NPSR1 747/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.